EXO-TBKi
Inflammatory diseases (via STING pathway/TBK1 inhibition)
Pre-clinicalActive
Key Facts
Indication
Inflammatory diseases (via STING pathway/TBK1 inhibition)
Phase
Pre-clinical
Status
Active
Company
About Exo Therapeutics
Exo Therapeutics, founded in 2017 and based in Cambridge, Massachusetts, is a private, pre-clinical stage biotech developing a new class of small molecule drugs. Its core innovation is targeting exosites—distinct, often allosteric sites on enzymes—to achieve selective inhibition or modulation, thereby tackling previously 'undruggable' targets. The company's pipeline, led by a TBK1 inhibitor program for inflammatory diseases, is built on its ExoSight™ discovery platform and is supported by a team with deep pharmaceutical industry expertise in drug development.
View full company profile